Massive medicare study reveals Real-World power of pneumonia vaccine in seniors
NCT ID NCT06782282
First seen Nov 21, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study looks at how effective the Prevnar 20 (PCV20) vaccine is at preventing serious infections like pneumonia and invasive pneumococcal disease in people aged 65 and older. Researchers will analyze medical records from over 22 million Medicare beneficiaries to compare those who got the vaccine with those who did not. No new treatments or vaccines are given—the study simply reviews existing data to measure real-world protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMUNITY-ACQUIRED PNEUMONIA (CAP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer United States
New York, New York, 10017, United States
Conditions
Explore the condition pages connected to this study.